Variation of serum lipoproteins in postmyocardial infarction patients treated with verapamil or placebo.
The effect of verapamil on plasma lipids and lipoproteins was studied in 64 patients taking part in a double blind controlled trial of verapamil versus placebo in post myocardial infarction. During a six month treatment period no significant difference was seen in plasma cholesterol, triglycerides, high density lipoproteins or low density lipoproteins.
D000328:Adult; D000368:Aged; D002784:Cholesterol / Q000097:blood; D005260:Female; D006801:Humans; D008074:Lipoproteins / Q000097:blood*; D008075:Lipoproteins, HDL / Q000097:blood; D008077:Lipoproteins, LDL / Q000097:blood; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000097:blood* / Q000188:drug therapy; D010919:Placebos; D014280:Triglycerides / Q000097:blood; D014700:Verapamil / Q000494:pharmacology* / Q000627:therapeutic use
D008074:Lipoproteins; D008075:Lipoproteins, HDL; D008077:Lipoproteins, LDL; D010919:Placebos; D014280:Triglycerides; D002784:Cholesterol; D014700:Verapamil